BROADCASTS.com

Health experts have been explaining why the jabs, meant for phase 1 of the country's COVID vaccination programme, failed to prevent mild and moderate cases of the new virus variant. WITS Professor, Shabir Madhi unpacked the results of a study on AstraZeneca in South Africa. 2 000 volunteers with no severe underlying comorbidities took part to establish the vaccine's safety. Madhi says the results were examined 14 days after their second dose. He says the vaccine trials before the emergence of the mutated virus showed promising results, but that changed once the new variant was detected.